**Pitt+Me Title**

Effectiveness and Safety Study of GSK3772847 in People With Moderately Severe Asthma

**Study Basics** *(400 character limit)*

Do you take a daily inhaled corticosteroid and bronchodilator for your moderate to severe asthma? If so, you may be able to take part in a research study to find out if an investigational study drug is a safe and effective treatment for asthma. Compensation is provided.

**Study Purpose**

Asthma is a chronic lung disease that causes wheezing, breathlessness, chest tightness, and coughing. Many people with severe asthma experience frequent asthma flare-ups even after taking currently available therapies like inhaled corticosteroids and bronchodilators.

The purpose of this study is to help researchers learn more about the safety and effectiveness of an investigational drug called GSK3772847 as your doctor gradually reduces the dose of your asthma inhalers. GSK3772847 is a type of drug called a monoclonal antibody that works with the body’s immune system to block a protein involved in asthma severity and inflammation of the lungs.

**Could This Study Be Right for You?**

- Ages 18 and up
- Diagnosed with moderate to severe asthma
- Currently taking an inhaled corticosteroid and an inhaled bronchodilator, either as a combination product or as separate inhalers
- Have had at least one asthma flare up in the past year that required the use of steroids and/or hospitalization
- Not a current smoker
- Former smokers must have a less than 10 pack year history (less than 1 pack a day for ten years or less than 2 packs a day for 5 years)

**What Participants Can Expect** *(1500 character limit)*

Participation involves 15 visits over 33 weeks. Most visits are 2 weeks apart. During the study, participants will have the following tests, assessments, and procedures: physical exams, medical history, blood and urine samples, pregnancy test, breathing tests, HIV test, electrocardiogram, heart monitoring, questionnaires, and at-home monitoring using a peak flow meter and electronic diary.

**AGE:** 18 and up  
**GENDER:** M/F  
**VISITS:** 15  
**DURATION:** About 33 weeks  
**LOCATION:** University of Pittsburgh Asthma Institute - Oakland  
**COMPENSATION:** Compensation is based on study visit completion
Eligible participants will be randomly assigned (like the flip of a coin) to receive either the investigational study drug or a placebo. A placebo is an inactive substance that looks like the study drug but does not contain any drug. Both the study drug and the placebo are given every 4 weeks by an intravenous infusion (IV, administration directly into a vein in the arm).

Before starting the study drug or placebo, participants will be asked to stop taking their current inhaled asthma medications and will be switched over to receive other inhaled asthma medications. The dose of these medications will be decreased every two weeks and then discontinued. If your asthma worsens, you will resume taking the inhaled medications you were taking before starting the study.

**IRB:** Advarra IRB# Pro00022479  A randomized, double-blind, parallel group, multicenter, stratified study evaluating the efficacy and safety of repeat doses of GSK3772847 compared with placebo in participants with moderately severe asthma

**MEET THE RESEARCHER**

Sally E. Wenzel, MD, has a passion for understanding and improving the treatment of asthma, particularly severe asthma. She served as Chair of the ATS workshop on severe asthma that developed the international consensus definition of severe asthma. Dr. Wenzel has been listed as one of Castle Connelly’s top doctors in America for over 10 years.